82results about How to "Inhibit oxidative stress" patented technology

A unique DHA product, 10, 17S-docosatriene (“Neuroprotectin D1” or “NPD1”), was found to provide surprisingly effective neuroprotection when administered right after an experimental stroke. Moreover, both nerve cells and retinal pigment epithelial (RPE) cells were found to synthesize 10,17S-docosatriene (NPD1) from DHA. NPD1 also potently counteracted H₂O₂/TNFα oxidative stress-mediated cell apoptotic damage. Under the same oxidative-stress conditions, NPD1 up-regulated the anti-apoptotic Bcl-2 proteins, Bcl-2 and Bcl-xL, and decreased expression of the pro-apoptotic proteins, Bad and Bax. Moreover, in RPE cells NPD1 inhibited oxidative stress-induced caspase-3 activation, IL-1β-stimulated human COX-2 promoter expression, and apoptosis due to N-retinylidene-N-retinylethanolamine (A2E). Overall, NPD1 protected both nerve and retinal pigment epithelial cells from cellular apoptosis and damage due to oxidative stress. NPD1 concentration in the brain of Alzheimer's patients was found to be significantly decreased from that of controls. In cultured human brain cells, NPD1 synthesis was up-regulated by neuroprotective soluble β amyloid, and NPD1 was found to inhibit secretion of toxic β amyloid peptides.

A pharmaceutical composition is provided comprising a therapeutically effective amount of pterostilbene, a therapeutically effective amount of curcumin, and a pharmaceutically acceptable carrier. The embodiments of the pharmaceutical compositions can have lipid lowering properties, or alternatively can have properties that can treat oxidative stress, by decreasing inflammation or inflammatory processes contributing to digestive disorders or cancer. A method of treating an individual for an inflammatory disorder is provided, comprising administering to the individual in need of such treatment a pharmaceutical composition including a therapeutically effective amount of pterostilbene, a therapeutically effective amount of a curcumin, and a pharmaceutically acceptable carrier. The combination containing pterostilbene and curcumin is effective for treatment or prevention of oxidative stress, treatment of digestive disorders including inflammatory bowel disease, and/or to reduce or inhibit inflammation, in both animals and in humans.

Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.

A method of treating and/or preventing oxidative damage, comprising administering an effective IsoK/NeuroK adduct formation suppressing amount of a phenolic amine compound and/or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.

The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within.

Veterinary supplements comprising one or more Nrf2-activating agents are disclosed. The veterinary supplements may further comprise omega-3 fatty acids and collagen. The veterinary supplements are effective for treating, inhibiting, reducing and/or preventing oxidative stress.

The invention discloses a hyaluronic acid skin protection composition. The hyaluronic acid skin protection composition comprises: 1) a sulfhydrylated derivative of hyaluronic acid; and 2) at least one molecular weight of hyaluronic acid or salt thereof. The composition has unique advantages when used for skin protection, not only has multiple skin protection effects of the hyaluronic acid, but also has strong antioxidant capacity, and can effectively scavenge active oxygen radicals.

In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.

The invention belongs to the field of research and development of polypeptide medicines and discloses a scorpion venom heat-resistant synthetic peptide and application thereof. An amino acid sequence of an SVHRP (scorpion venom heat-resistant peptide) is detected out from BmK (Buthus martensii Karsch) which is a traditional Chinese medicine; according to animal experiment verification, a scorpion venom heat-resistant peptide extract liquid sample has pharmacological activity in prevention and treatment of intractable epilepsy, Parkinson's disease and Alzheimer's disease, the sample is subjected to LaGm composite and repeated fast magnetic separation prior to nanoLC-ESI-MS (nano-liter reversed-phase chromatography and electrospray ionization mass spectrometry) integrated mass spectrometry parallel experiment to detect out a polypeptide sequence formed by 15 amino acid residues. The scorpion venom heat-resistant synthetic peptide is prepared by solid-phase chemical synthesis, chromatography purification and mass spectrometry identification. An amino acid sequence of the scorpion venom heat-resistant synthetic peptide is as shown in SEQ ID NO.1 and keeps pharmacological activity and safety of the scorpion venom heat-resistant peptide, and the scorpion venom heat-resistant peptide also has a characteristic of biological activity in promotion of reverse differentiation of neuroglial cells into neural stem cells.

The present invention relates to neural cell survival, differentiation and proliferation promoting peptide fragments derived from metallothioneins (MT), pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of diseases and conditions where the effects of stimulating neural cell proliferation, differentiation and/or survival, and/or stimulating neural plasticity associated with learning and memory are beneficial for treatment.

The invention relates to the technical field of biological medicines. That miR-144 can specifically inhibit the gene expression of Nrf2 is disclosed for the first time, the expression of miR-144 is closely related to heart disease, and the high expression of miR-144 can promote myocardial oxidative stress to cause myocardial damage related diseases. The invention provides miR-144 and application of an inhibitor of miR-144 in preparation of medicines for preventing or treating myocardial oxidative stress and damage diseases, especially diabetes caused myocardial oxidative stress and damage diseases; a new target spot is provided for the diagnosis and prevention and treatment of heart diseases.

The invention relates to a biological medicine domain, particularly a pharmaceutical application of a protein associated with activation of human hepatic stellate cell, namely an application of preparation of medicine for liver diseases. The invention also discloses a recombination preparation method.

The invention discloses application of irisin in the preparation of drugs for preventing myocardial ischemia reperfusion injuries. Experimental results show that irisin can decrease the myocardial infarction area caused by ischemia reperfusion, reduce the increase of the contents of lactate dehydrogenase (LDH), troponin (cTnI), creatine kinase (CK), and other myocardial enzyme markers caused by ischemia reperfusion, meanwhile reducing the inflammatory response, myocardial apoptosis, and oxidative stress response caused by myocardial ischemia reperfusion, promote peroxysome proliferator-activated receptor γ nuclear translocation, and inhibit nuclear transcription factor NF-κB nuclear translocation and accordingly decrease myocardial structure injuries and load increase caused by ischemia reperfusion. Therefore, irisin can be used for preventing and decreasing myocardial reperfusion injuries and has important clinical significance on the treatment of myocardial ischemia.

The invention provides an application of dendrobium polysaccharide in the preparation of drugs for prevention and treatment of reproductive injury caused by arsenic poisoning. The dendrobium polysaccharide has obvious therapeutic effect on reproductive injury induced by arsenic exposure in male rats, which can significantly increase the number and motility of sperms, increase the incidence of sperm acrosome reaction and decrease the rate of sperm deformity; the SOD activity, GPx activity, CAT activity and GSH content in testicular tissue are also significantly increased, while MDA content is also significantly decreased; the dendrobium polysaccharide has rarely toxic and side effects and no adverse effect on normal growth and physiological state. The dendrobium polysaccharide with wide source of raw materials is simple in extraction and purification method, high in sugar content and suitable for large-scale production and promotion and has a good prospect in the preparation and/or treatment of reproductive injury drugs caused by arsenic poisoning and clinical application.

An Echinozoa tissue or organ extract comprising antioxidant compounds is disclosed. Also disclosed is a process for obtaining an Echinozoa tissue or organ extract, as well an extract obtained by this process. Compositions comprising such an extract are also described. Uses of such extracts/compositions, as well as corresponding methods of treatment, for example as an antioxidant or to decrease or inhibit oxidative stress in a cell, tissue or subject are also described.

The invention discloses an application of oltipraz in preparation of a product for preventing and treating osteoporosis. The application comprises any one of the following items: 1) preparing a product for preventing and treating osteoporosis caused by lack of active vitamin D; 2) preparing a product for preventing and treating osteoporosis caused by estrogen deficiency; and 3) preparing a product for preventing and treating osteoporosis caused by vitamin D receptor deficiency. According to the invention, through a test of supplementing an Nrf2 agonistoltiprazto a mouse model, the effect and related mechanism of oltipraz in preventing and treating osteoporosis caused by lack of active vitamin D are disclosed, and meanwhile, experimental and theoretical bases are provided for the application of oltipraz in preventing and treating osteoporosis caused by estrogen deficiency.

The invention relates to application of mulberry particles to preparation of medicines for preventing and treating diabetes and complications thereof. The complications refer to one of cardiovascular diseases, cerebrovascular diseases, renal injuries and vascular injuries. The mulberry particles are especially excellent in prevention and treatment effect on cardiovascular disease complications of diabetes and particularly prominent in treatment effect on cardiac dysfunction, myocardial injuries or myocardial infarction caused by myocardial ischemia. Furthermore, the mulberry particles are effective in control of in-vivo blood sugar and blood lipid level of patients suffering from diabetes, capable of improving cardiac dysfunction caused by myocardial ischemia with diabetes and effective in inhibition of oxidative stress.